Newsroom

GURUGRAM, India--(BUSINESS WIRE)--ReNew has secured $95 million equity investment from LeapFrog-led consortium to expand its Commercial & Industrial platform....

BRUSSELS--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) Europe will hold an advocacy action in Brussels on March 18 at 11:00 a.m. CET on Archimedes Street, followed by an in-person and virtual press conference at Press Club Brussels Europe titled “EU: Stop Blocking Health Equity,” urging European Commission (EC) decision-makers to support a legally binding Pathogen Access and Benefit-Sharing (PABS) Annex to the WHO Pandemic Agreement. Click here to access the Press conference Zoom link, and...

ARLINGTON, Va,--(BUSINESS WIRE)--CoStar Group, Inc. (NASDAQ: CSGP), a leading provider of online real estate marketplaces, information, analytics, and 3D digital twin technology in the property markets, today announced that Nana Banerjee has been appointed as a new independent member of the Company’s Board of Directors (the “Board”), effective immediately. With this appointment, the Board expands to nine directors, eight of whom are independent. Nana Banerjee brings more than two decades of exp...

AMSTERDAM--(BUSINESS WIRE)--Assurant, Inc. (NYSE: AIZ), a premier global protection company that safeguards and services connected devices, homes and automobiles in partnership with the world’s leading brands, announced a new partnership with hollandsnieuwe, one of the Netherlands’ top online mobile operators, to bring mobile device protection to hollandsnieuwe customers for the very first time. This collaboration marks an important milestone in Assurant’s continued expansion in the Dutch marke...

ACCRA, Ghana--(BUSINESS WIRE)--RevnaBio today announced that it has received triple accreditation from the American Association for Laboratory Accreditation (A2LA), validating its laboratory and biobanking operations under three internationally recognized standards: ISO 15189 for medical laboratories, ISO 20387 for biobanking, and ISO/IEC 17043 for proficiency testing providers. The combined accreditation confirms the strength of RevnaBio’s integrated quality systems across clinical diagnostics...

ST. ANDREWS, Scotland--(BUSINESS WIRE)--The R&A and Accenture announced a six-year partnership where Accenture will become the Official Business and Technology Consulting Partner of The R&A....

LONDON--(BUSINESS WIRE)--Accenture (NYSE: ACN) has completed the acquisition of Faculty, a leading UK‑based AI company known for its deep technical expertise and pedigree in applying AI safely across public and private sectors to help clients improve services and deliver growth. With the acquisition completed, Faculty CEO and co-founder Dr. Marc Warner expands his role to also become chief technology officer of Accenture and joins the company’s Global Management Committee. “Now that Faculty is...

PARIS LA DÉFENSE--(BUSINESS WIRE)--Regulatory News: Arkema (Paris:AKE) unveils a 20% expansion of its Kynar® PVDF production capacity at its Changshu site in China, with the new unit expected to start up in 2028. This additional capacity is designed to support the strong and sustained growth in demand for Kynar® PVDF across all key markets, including lithium-ion batteries for electric vehicles (EV) and energy storage systems (ESS), high-performance coatings, chemical processing industries, semi...

PARIS LA DÉFENSE--(BUSINESS WIRE)--Regulatory News : Arkema (Paris:AKE) dévoile une expansion de 20 % de sa capacité de production de PVDF Kynar® sur son site de Changshu en Chine, cette nouvelle unité devant démarrer en 2028. Cette capacité additionnelle est destinée à accompagner la croissance robuste et soutenue de la demande de PVDF Kynar® sur l’ensemble des marchés clés, comme les batteries lithium-ion pour véhicules électriques et systèmes de stockage d'énergie, les revêtements haute perf...

WHIPPANY, N.J.--(BUSINESS WIRE)--The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD) — has met its primary endpoint.1 The results demonstrated a statistically significant improvement versus placebo in the primary efficacy outcome of estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change from...